Elicio Therapeutics, Inc. (ELTX) stock
ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.59+0.16 (+11.19%)
Close on Nov 18, 2026Market cap $41.79MP/E –Yield –
Elicio Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Elicio Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$36.97M. For fiscal 2025 it was -$36.97M. The highest annual figure on record is -$22.83M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.97M | – |
| FY2024 | Dec 31, 2024 | -$37.16M | – |
| FY2023 | Dec 31, 2023 | -$32.76M | – |
| FY2022 | Dec 31, 2022 | -$22.83M | – |
| FY2021 | Dec 31, 2021 | -$53.03M | – |
| FY2020 | Dec 31, 2020 | -$22.93M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$6.81M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.79M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.48M | -270.0% |
| Q1 FY2023 | Mar 31, 2023 | -$8.16M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.39M | – |
| Q2 FY2022 | Jun 30, 2022 | $5.58M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.65M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.40M | -170.0% |
| Q3 FY2021 | Sep 30, 2021 | -$15.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.59M | – |
| Q4 FY2020 | Dec 31, 2020 | $20.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.94M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.81M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.75M | – |
See a number that looks wrong?